Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2017
Event: Entry into a Material Definitive Agreement involving the issuance of convertible promissory notes.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or existing debt levels. The primary financial metric disclosed is the new debt obligation:
- New Debt Issued: $2,000,000 total ($1,000,000 to The Musculoskeletal Transplant Foundation and $1,000,000 to Hankey Capital, LLC).
- Interest Rate: 8.5% per annum.
- Maturity Date: December 31, 2017.
- Conversion Price: $1.00 per share of common stock.
Material Changes
The company has entered into a Note Purchase Agreement to secure funding. Proceeds are restricted for use in prioritizing essential research and development activities. The filing incorporates by reference the terms of unregistered sales of equity securities (the Convertible Notes) issued under Section 4(a)(2) of the Securities Act of 1933 to accredited investors.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use the proceeds to focus on essential R&D operations.
Contingencies: In the event of a future financing resulting in gross proceeds of at least $5,000,000 from non-current stockholders, the Convertible Notes must be converted into the same securities issued in that financing at the same price per share.
Risks: The filing does not explicitly list risk factors beyond the standard obligations of the debt instrument and the requirement for future conversion under specific financing conditions.
Investor Verification Checklist
- Verify the company's current cash position to assess the necessity of this debt financing.
- Confirm the dilution impact if the notes are converted at the $1.00 per share rate.
- Review the full Note Purchase Agreement (Exhibit 10.1) for covenants not summarized in the 8-K.
- Monitor for any future financing events exceeding $5,000,000 that would trigger mandatory conversion.